← Leaderboards
Bryan Michael Burt
Baylor College Of Medicine
$3,339,861
Attributed
$4,514,799
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,514,799 · 4
By mechanism
R37$2,492,667 · 1
R01$1,762,407 · 1
R03$158,500 · 1
F32$101,225 · 1
Top collaborators
- Livia Schiavinato Eberlin3 shared
- Justin Wiseman3 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Malcolm K Brenner$13,204,649
- Helen E Heslop$25,308,937
- Robert Taylor Ripley$2,243,195
- Justin Wiseman$587,469
- Maria Jose Redondo$6,367,198
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsOperative Surgical ProceduresCaringProspectiveTissuesT-LymphocyteTranslatingLungPatient CareValidationMass Spectrum AnalysisStandard Of CareSpecimenCellsFrequenciesImmuneInnovationDesignResponseMalignant Pleural MesotheliomaToxic EffectImmunologicsElements
Grant awards (12)
Validation and Translation of MasSpec Pen Technology for Intraoperative Evaluation of Non-small Cell Lung Cancer$603,561
R01 · FY2025 · CA
Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma$449,641
R37 · FY2025 · CA · contact PI
Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma$584,543
R37 · FY2024 · CA · contact PI
Validation and Translation of MasSpec Pen Technology for Intraoperative Evaluation of Non-small Cell Lung Cancer$557,296
R01 · FY2024 · CA
Validation and Translation of MasSpec Pen Technology for Intraoperative Evaluation of Non-small Cell Lung Cancer$601,550
R01 · FY2023 · CA
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesothelioma$495,857
R37 · FY2023 · CA · contact PI
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesothelioma$508,688
R37 · FY2022 · CA · contact PI
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesothelioma$453,938
R37 · FY2021 · CA · contact PI
Allogeneic antibody therapy for malignant mesothelioma$79,250
R03 · FY2017 · CA · contact PI
Allogeneic antibody therapy for malignant mesothelioma$79,250
R03 · FY2016 · CA · contact PI
Natural Killer Dendritic Cells in Cancer$50,797
F32 · FY2007 · CA · contact PI
Natural Killer Dendritic Cells in Cancer$50,428
F32 · FY2006 · CA · contact PI